Erratum: In older men, lower plasma 25-hydroxyvitamin D is associated with reduced incidence of prostate, but not colorectal or lung cancer (PLoS ONE (2014) 9, 6 (e99954) DOI: 10.1371/journal.pone.0099954);In older men, lower plasma 25-hydroxyvitamin D is associated with reduced incidence of prostate, but not colorectal or lung cancer

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Wong, Yuen Y E ^a,b   Hyde, Zoë ^a,b   McCaul, Kieran A ^b   Yeap, Bu B ^b,c   Golledge, Jonathan ^d,e   Hankey, Graeme J ^b,f   Flicker, Leon ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c FREMANTLE HOSPITAL   (Australia)

^d JAMES COOK UNIVERSITY   (Australia)

^e TOWNSVILLE HOSPITAL   (Australia)

^f SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; 25-HYDROXYVITAMIN D; VITAMIN D;

AGED; ARTICLE; AUSTRALIA; BLOOD SAMPLING; CALCIFEDIOL BLOOD LEVEL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; FOLLOW UP; HUMAN; IMMUNOASSAY; LUNG CANCER; MALE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK REDUCTION; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; COLORECTAL TUMOR; LUNG TUMOR; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; VITAMIN D;

EID: 84903292647     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109511     Document Type: Erratum

References (44)

1. Cancer Research UK (2011) CancerStats Cancer Worldwide. September; Available: http://publications.cancerresearchuk.org/downloads/Product/CS-CS- WORLD.pdf Accessed May 2013.
2. Chiang KC, Chen TC (2013) The Anti-cancer Actions of Vitamin D. Anticancer Agents Med Chem 13: 126-139.
3. Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews Cancer 7: 684- 700.
4. Baeke F, van Etten E, Gysemans C, Overbergh L, Mathieu C (2008) Vitamin D signaling in immune-mediated disorders: Evolving insights and therapeutic opportunities. Molecular Aspects of Medicine 29: 376-387.
5. Autier P, Boniol M, Pizot C, Mullie P (2014) Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2: 76-89.
6. Pilz S, Kienreich K, Tomaschitz A, Ritz E, Lerchbaum E, et al. (2013) Vitamin d and cancer mortality: systematic review of prospective epidemiological studies. Anticancer Agents Med Chem 13: 107-117.
7. Lazzeroni M, Serrano D, Pilz S, Gandini S (2013) Vitamin d supplementation and cancer: review of randomized controlled trials. Anticancer Agents Med Chem 13: 118-125.
8. Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z, et al. (2009) Cohort Profile: The Health In Men Study (HIMS). International Journal of Epidemiology 38: 48-52.
9. Holman CD, Bass AJ, Rouse IL, Hobbs MS (1999) Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23: 453-459. (Pubitemid 29479210)
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383. (Pubitemid 17055592)
11. Norton K, Whittingham N, Carter L, Kerr D, Gore C, et al. (2000) Measurement techniques in anthropometry. In: Norton K, Olds T, ed. Anthropometrica Sydney, Australia: UNSW Press:27-75.
12. Wong YY, Flicker L, Yeap BB, McCaul KA, Hankey GJ, et al. (2013) Is hypovitaminosis D associated with abdominal aortic aneurysm, and is there a dose-response relationship? Eur J Vasc Endovasc Surg 45: 657-664.
13. Fine J, Gray R (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94: 496-509.
14. Holick MF (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81: 353-373.
15. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, et al. (1997) Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7: 439-443. (Pubitemid 27443069)
16. Wong YY, McCaul KA, Yeap BB, Hankey GJ, Flicker L (2013) Low vitamin D status is an independent predictor of increased frailty and all-cause mortality in older men: the Health In Men Study. J Clin Endocrinol Metab.
17. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, et al. (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108: 104-108. (Pubitemid 37444451)
18. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, et al. (2007) Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate 67: 911-923. (Pubitemid 46828925)
19. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, et al. (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100: 796-804. (Pubitemid 351809669)
20. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF (1998) Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25- hydroxyvitamin D3. Cancer Epidemiology, Biomarkers & Prevention 7: 391- 395.
21. Barreto AM, Schwartz GG, Woodruff R, Cramer SD (2000) 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiology, Biomarkers & Prevention 9: 265-270. (Pubitemid 30165438)
22. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, et al. (2002) 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. Journal of Steroid Biochemistry & Molecular Biology 81: 135-140. (Pubitemid 34876404)
23. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, et al. (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiology, Biomarkers & Prevention 2: 467-472.
24. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, et al. (1996) Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 5: 121-126.
25. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, et al. (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes & Control 9: 425-432. (Pubitemid 28466695)
26. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes & Control 11: 847-852.
27. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, et al. (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Medicine/Public Library of Science 4: e103.
28. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, et al. (2013) Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J Steroid Biochem Mol Biol 136: 233-237.
29. Beer TM, Myrthue A, Garzotto M, O'Hara M F, Chin R, et al. (2004) Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 13: 2225-2232. (Pubitemid 40054321)
30. Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, et al. (2010) Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study. BMJ 340: b5500.
31. Woolcott CG, Wilkens LR, Nomura AM, Horst RL, Goodman MT, et al. (2010) Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 19: 130-134.
32. Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, et al. (2007) A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 99: 1120-1129. (Pubitemid 47241396)
33. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S (2007) Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. Br J Cancer 97: 446-451. (Pubitemid 47196759)
34. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW (1995) Colon cancer and serum vitamin Dmetabolite levels 10-17 years prior to diagnosis. Am J Epidemiol 142: 608-611.
35. Ma Y, Zhang P, Wang F, Yang J, Liu Z, et al. (2011) Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 29: 3775-3782.
36. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, et al. (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354: 684-696. (Pubitemid 43247139)
37. Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326: 469.
38. Kilkkinen A, Knekt P, Heliovaara M, Rissanen H, Marniemi J, et al. (2008) Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol Biomarkers Prev 17: 3274-3278.
39. Weinstein SJ, Yu K, Horst RL, Parisi D, Virtamo J, et al. (2011) Serum 25- hydroxyvitamin D and risk of lung cancer in male smokers: a nested case-control study. PLoS One 6: e20796.
40. Ordonez-Mena JM, Schottker B, Haug U, Muller H, Kohrle J, et al. (2013) Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prev 22: 905- 916.
41. Afzal S, Bojesen SE, Nordestgaard BG (2013) Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem 59: 771-780.
42. Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T (2005) 22-Oxa-1alpha, 25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26: 1044-1054. (Pubitemid 41214297)
43. Ranasinghe W, Kim SP, Lawrentschuk N, Sengupta S, Hounsome L, et al. (2013) Population based analysis of Prostate Specific Antigen (PSA) screening in younger men (,55 years) in Australia. BJU Int.
44. Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckhardt P, et al. (2010) IOF position statement: vitamin D recommendations for older adults. Osteoporos Int 21: 1151-1154.